SF3B1 and myeloproliferative disorder: Malcovati et al. studied the clinical significance of SF3B1 mutations in MDS and MDS/MPN, reporting that the presence of SF3B1 mutation has a positive predictive value for disease phenotype with ring sideroblasts of 97.7%, and the absence of this mutation has a negative predictive value of 97.8% [141].